Description
A triple agonist of GLP-1, GIP, and glucagon receptors (LY3437943). Retatrutide has demonstrated unprecedented weight loss (~24% in 48 weeks in humans) by combining the effects of GLP-1/GIP (insulin secretion, appetite suppression) with glucagon’s increase of energy expenditure[23][24]. 5 mg vials are for initial testing. In obese rodent studies, retatrutide drastically improves glucose tolerance, induces fat oxidation, and even reduces liver fat and fibrosis due to its glucagon activity.
15 mg dose. Triple agonists like retatrutide are being studied for cardiovascular benefits (the glucagon component can improve cardiac output and induce browning of fat). This higher dose kit supports long-duration studies on heart and kidney function in obese, diabetic models, to assess organ-protective effects alongside weight loss.




Reviews
There are no reviews yet.